PharmaMar's Lurbinectedin Granted as Orphan drug designation by U.S. FDA for Small Cell Lung Cancer(SCLC)
Shots:
- Lurbinectedin (PM1183) a compound under clinical investigation an inhibitor of RNA polymerase II- essential for transcription process that is over-activated in tumors with transcription addiction
- The designation may provide certain benefits- with a 7-year market exclusivity if approved leading to an exemption from FDA fees
- SCLC is an aggressive cancer ~18% cancer diagnosed with SCLC- with a number of 34-000 new cases in US aloneRef: US FDA | Image: PRNeewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
